Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin

Circulation Research
J S StamlerJ Loscalzo

Abstract

Endothelial cells produce at least three substances that can attenuate the platelet aggregation response: tissue-type plasminogen activator; the platelet inhibitory prostaglandins I2 and E1; and endothelium-derived relaxing factor, one form of which exhibits properties of nitric oxide. Since platelet aggregates formed in vivo are involved in the initiation of many clinically important occlusive vascular syndromes, we tested the hypothesis that these endothelial products act synergistically to disperse platelet aggregates. Our data reveal that tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin (an organic nitrate activator of guanylate cyclase analogous to endothelium-derived relaxing factor) act synergistically to disaggregate platelets and do so in part by modulation of platelet cyclic nucleotides. These data suggest a potential mechanism by which the endothelium protects against the formation of platelet aggregates in vivo and offer a potential strategy for improving the efficacy of thrombolytic therapy.

References

Jun 1, 1987·The Journal of Clinical Investigation·J Loscalzo, D E Vaughan
Aug 1, 1985·The Journal of Clinical Investigation·J Loscalzo
Sep 1, 1988·The American Journal of Cardiology·J StamlerJ Loscalzo
Nov 28, 1985·The New England Journal of Medicine·J A CairnsM G Myers
Jun 7, 1985·Journal of Theoretical Biology·M C Berenbaum
Nov 1, 1970·British Journal of Haematology·R L Kinlough-RathboneJ F Mustard
Nov 1, 1982·Molecular and Cellular Endocrinology·J A BeavoM C Mumby
Aug 1, 1963·The Journal of Physiology·G V BORN, M J CROSS

❮ Previous
Next ❯

Citations

Dec 1, 1991·Trends in Cardiovascular Medicine·J S Stamler, J Loscalzo
Sep 1, 1995·Progress in Cardiovascular Diseases·J Loscalzo, G Welch
Mar 1, 1991·Journal of the American College of Cardiology·J L MehtaT G Saldeen
Feb 10, 2000·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·V B Schini-Kerth
Jul 9, 2003·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·P GreseleA M Mezzasoma
Sep 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J S StamlerJ Loscalzo
May 7, 2010·Antioxidants & Redox Signaling·Jane A Leopold
Jan 1, 1992·Acta Anaesthesiologica Scandinavica. Supplementum·H Johnsson
Jul 1, 1995·Pharmacology & Toxicology·R J Gryglewski
Feb 15, 1996·The Journal of Clinical Investigation·J E FreedmanA D Michelson
Jan 1, 1996·Platelets·D BlockmansJ Vermylen
Jun 1, 1995·Annals of Medicine·R J Gryglewski
Nov 10, 2006·International Journal of Cardiology·Panuratn ThanyasiriMark R Adams
Jun 1, 1994·The American Journal of Cardiology·L L LacosteJ Y Lam
May 15, 1991·Thrombosis Research·G H RaoJ G White
Jul 1, 1994·American Heart Journal·N J Mangione, S P Glasser
Apr 30, 2017·Journal of Thrombosis and Haemostasis : JTH·A Smolenski
Oct 3, 2003·Journal of Thrombosis and Haemostasis : JTH·G Walford, J Loscalzo
Jul 15, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Panuratn ThanyasiriMark R Adams
Sep 29, 1999·Cardiovascular and Interventional Radiology·S RoyK S Sakariassen
Jan 4, 1990·The New England Journal of Medicine·B S Coller
Jul 27, 2018·Research and Practice in Thrombosis and Haemostasis·Zoltan Nagy, Albert Smolenski
Jan 1, 1996·Vascular Medicine·G R UpchurchJ Loscalzo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.